Literature DB >> 18460249

Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.

Khurshid Ahmed Khan1, Ayesha Junaid, Nauman Saleem Siddiqui, Khalida Mukhtar, Saleem Siddiqui.   

Abstract

Imatinib mesylate is a BCR-ABL tyrosine kinase inhibitor used in the management of chronic myeloid leukemia. It is a safe and well-tolerated agent with a few manageable side effects. We are reporting a case of imatinib-related fatal bone marrow aplasia after complete cytogenetic response.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18460249     DOI： 03.2008/JCPSP.176178

Source DB:  PubMed          Journal:  J Coll Physicians Surg Pak        ISSN： 1022-386X            Impact factor:   0.711


  5 in total

1.  Evaluation of Cytopenias Occurring in Imatinib Treated Chronic Myeloid Leukemia (CML) Patients.

Authors:  T Roshni Paul; Shantveer G Uppin; Megha S Uppin; Rachel T Jacob; D Raghunadha Rao; Senthil J Rajappa
Journal:  Indian J Hematol Blood Transfus       Date:  2010-10-05       Impact factor: 0.900

2.  Synchronous presentation of chronic myeloid leukemia with carcinoma penis: a rare presentation.

Authors:  Abhijeet P Ganapule; Vivi Srivasvas Tavaavaava; Ramani Manoj Kumar; Nirmal T J; Auro Viswabandya
Journal:  J Clin Diagn Res       Date:  2014-09-20

3.  Aplasia in Chronic Phase CML Post-TKI Therapy: A Management Dilemma.

Authors:  Jeremy L Ramdial; Luis E Aguirre; Robert A Ali; Ronan Swords; Mark Goodman
Journal:  Case Rep Hematol       Date:  2019-09-22

4.  Ethnic Differences in Hematologic Toxicity from Imatinib in Patients with Gastrointestinal Stromal Cell Tumor (GIST): Coincidence or a Real Phenomenon.

Authors:  Muhammad Wasif Saif; Sneha Purvey; Kristin Kaley; Nawal Wasif; Annmarie Carmel; Teresa Rodriguez; Kenneth B Miller
Journal:  Eurasian J Med Oncol       Date:  2019

5.  MDR1/ABCB1 gene polymorphisms in patients with chronic myeloid leukemia.

Authors:  Mabel Lardo; Marcelo Castro; Beatriz Moiraghi; Francisca Rojas; Natalia Borda; Jorge A Rey; Alberto Lazarowski
Journal:  Blood Res       Date:  2015-09-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.